Literature DB >> 197125

Regulation of rabbit myometrial alpha adrenergic receptors by estrogen and progesterone.

L T Williams, R J Lefkowitz.   

Abstract

The effects of estrogen and progesterone on uterine alpha-adrenergic receptors were investigated by direct receptor-binding studies. Immature female rabbits were primed with estrogen by intramuscular injections for 4 days. Other rabbits were primed with progesterone by injections of estrogen for 4 days followed by injections of progesterone for 4 days. The alpha adrenergic antagonist, [3H]dihydroergocryptine, was used to directly assess the number and affinity of alpha adrenergic receptors in membranes derived from estrogen-and progesterone-primed uteri. Membranes from estrogen-primed uteri contained 257 +/- 52 fmol of [3H]dihydroergocryptine-binding sites per mg protein whereas membranes from progesterone-primed uteri contained 83 +/- 11 fmol of of binding sites per mg protein. This reduction of alpha adrenergic receptor-binding sites by progesterone was statistically significant (P less than 0.02). In contrast, no significant difference in the binding site affinity was observed between the estrogen- and progesterone-primed groups. The progesterone-induced decrease in the number of uterine alpha adrenergic receptors provides a potential explanation for the reduced alpha adrenergic contractile response to epinephrine in the progesterone-primed myometrium.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 197125      PMCID: PMC372429          DOI: 10.1172/JCI108835

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Effect of 1-norepinephrine infusion on uterine contractility and cardiovascular system.

Authors:  L A CIBILS; S V POSE; F P ZUSPAN
Journal:  Am J Obstet Gynecol       Date:  1962-08-01       Impact factor: 8.661

2.  Molecular pharmacology of alpha adrenergic receptors: utilization of [3H]dihydroergocryptine binding in the study of pharmacological receptor alterations.

Authors:  L T Williams; R J Lefkowitz
Journal:  Mol Pharmacol       Date:  1977-03       Impact factor: 4.436

3.  Effect of 1-epinephrine infusion on uterine contractility and cardiovascular system.

Authors:  S V POSE; L A CIBILS; F P ZUSPAN
Journal:  Am J Obstet Gynecol       Date:  1962-08-01       Impact factor: 8.661

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  beta-adrenergic receptors in rat liver: effects of adrenalectomy.

Authors:  B B Wolfe; T K Harden; P B Molinoff
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

Review 6.  Pharmacology of the uterus.

Authors:  L A Cibils; F P Zuspan
Journal:  Clin Obstet Gynecol       Date:  1968-03       Impact factor: 2.190

7.  Comparison of alpha- and beta-receptor stimulation in the circular and longitudinal muscle of the oestrogen and progesterone dominated rabbit uterus.

Authors:  B I Nesheim
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-04

8.  Thyroid hormone regulation of beta-adrenergic receptor number.

Authors:  L T Williams; R J Lefkowitz; A M Watanabe; D R Hathaway; H R Besch
Journal:  J Biol Chem       Date:  1977-04-25       Impact factor: 5.157

9.  Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol binding.

Authors:  L T Williams; R Snyderman; R J Lefkowitz
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

10.  Identification of cardiac beta-adrenergic receptors by (minus) [3H]alprenolol binding.

Authors:  R W Alexander; L T Williams; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

View more
  14 in total

1.  Increase by oestrogen of calcium entry and calcium channel density in uterine smooth muscle.

Authors:  S Batra
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

Review 2.  Hormonal and local regulation of uterine activity during parturition: Part II--The prostaglandin and adrenergic systems.

Authors:  M Maggi; E Baldi; T Susini
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

3.  Beta-adrenergic receptors in DMBA-induced rat mammary tumors: correlation with progesterone receptor and tumor growth.

Authors:  B Marchetti; P G Spinola; M Plante; P Poyet; N Folléa; G Pelletier; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

4.  Oxygen consumption of oestradiol-treated rats.

Authors:  A Fernández; M Abelenda; M P Nava; M Puerta
Journal:  Pflugers Arch       Date:  1994-02       Impact factor: 3.657

5.  Effects of ovarian steroids upon responses mediated by adrenoceptors in separated layers of the myometrium and in the costo-uterine muscle of the guinea-pig.

Authors:  M L Hartley; J N Pennefather; M E Story
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

6.  The role of the sympathetic nervous system in oestrogen-induced hypertension in rats.

Authors:  J D Bhatt; O D Gulati
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

7.  Steroid hormone modulation of cAMP production in response to beta adrenergic receptor stimulation in genital tract myocytes.

Authors:  L DiGiovanni; R Austin; M Phillippe
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

8.  Refractoriness of the gravid rat uterus to tocolytic and biochemical effects of atrial natriuretic peptide.

Authors:  W Potvin; D R Varma
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

9.  Progesterone and oestradiol increase cytosolic Ca2+ in single rat hepatocytes.

Authors:  A Sanchez-Bueno; M J Sancho; P H Cobbold
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

10.  Natural progesterone and antihypertensive action.

Authors:  P B Rylance; M Brincat; K Lafferty; J C De Trafford; S Brincat; V Parsons; J W Studd
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.